LIVIVO - Search results -

Search results

Result 1 - 10 of total 58

Article ; Online: Preface.

Boissan, Mathieu

2023 Volume 42, Issue 4, Page(s) 1069

Language	English
Publishing date	2023-11-08
Publishing country	Netherlands
Document type	Editorial
ZDB-ID	604857-2
ISSN	1573-7233 ; 0167-7659
ISSN (online)	1573-7233
ISSN	0167-7659
DOI	10.1007/s10555-023-10151-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1812: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Mechanisms of action of NME metastasis suppressors - a family affair.

Prunier, Céline / Chavrier, Philippe / Boissan, Mathieu

Cancer metastasis reviews

2023 Volume 42, Issue 4, Page(s) 1155–1167

Abstract: Metastatic progression is regulated by metastasis promoter and suppressor genes. NME1, the prototypic and first described metastasis suppressor gene, encodes a nucleoside diphosphate kinase (NDPK) involved in nucleotide metabolism; two related family ... ...

Abstract	Metastatic progression is regulated by metastasis promoter and suppressor genes. NME1, the prototypic and first described metastasis suppressor gene, encodes a nucleoside diphosphate kinase (NDPK) involved in nucleotide metabolism; two related family members, NME2 and NME4, are also reported as metastasis suppressors. These proteins physically interact with members of the GTPase dynamin family, which have key functions in membrane fission and fusion reactions necessary for endocytosis and mitochondrial dynamics. Evidence supports a model in which NDPKs provide GTP to dynamins to maintain a high local GTP concentration for optimal dynamin function. NME1 and NME2 are cytosolic enzymes that provide GTP to dynamins at the plasma membrane, which drive endocytosis, suggesting that these NMEs are necessary to attenuate signaling by receptors on the cell surface. Disruption of NDPK activity in NME-deficient tumors may thus drive metastasis by prolonging signaling. NME4 is a mitochondrial enzyme that interacts with the dynamin OPA1 at the mitochondria inner membrane to drive inner membrane fusion and maintain a fused mitochondrial network. This function is consistent with the current view that mitochondrial fusion inhibits the metastatic potential of tumor cells whereas mitochondrial fission promotes metastasis progression. The roles of NME family members in dynamin-mediated endocytosis and mitochondrial dynamics and the intimate link between these processes and metastasis provide a new framework to understand the metastasis suppressor functions of NME proteins.
MeSH term(s)	Humans ; NM23 Nucleoside Diphosphate Kinases/genetics ; NM23 Nucleoside Diphosphate Kinases/metabolism ; Dynamins/metabolism ; Neoplasms/pathology ; Cell Membrane/metabolism ; Guanosine Triphosphate
Chemical Substances	NM23 Nucleoside Diphosphate Kinases ; Dynamins (EC 3.6.5.5) ; Guanosine Triphosphate (86-01-1)
Language	English
Publishing date	2023-06-24
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	604857-2
ISSN	1573-7233 ; 0167-7659
ISSN (online)	1573-7233
ISSN	0167-7659
DOI	10.1007/s10555-023-10118-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1812: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Caractéristiques immuno-analytiques du PSA et des biomarqueurs dérivés (PSA total, PSA libre et P2ProPSA).

Desbène, Cédric / Boissan, Mathieu / Loric, Sylvain / Lamy, Pierre-Jean / Piéroni, Laurence

Annales de biologie clinique

2023 Volume 81, Issue 1, Page(s) 7–23

Abstract: Prostate-specific antigen (PSA) is the recommended tumor marker for individual screening and follow-up of prostate cancer. This paper reviews main structural and physiological data about prostate specific antigen isoforms: total PSA, free PSA, [-2]proPSA ...

Title translation	Immuno-analytical characteristics of PSA and derived biomarkers (total PSA, free PSA, p2PSA).
Abstract	Prostate-specific antigen (PSA) is the recommended tumor marker for individual screening and follow-up of prostate cancer. This paper reviews main structural and physiological data about prostate specific antigen isoforms: total PSA, free PSA, [-2]proPSA (also named p2PSA). It describes the pre-, per- and post-analytical conditions for these different parameters. It presents the interpretation of results and derived calculated indices (free/total PSA ratio, Prostate Health Index or PHI) for the management of prostate cancer (initial diagnosis and follow-up).
MeSH term(s)	Male ; Humans ; Prostate-Specific Antigen ; Protein Precursors ; Biomarkers, Tumor ; Protein Isoforms ; Prostatic Neoplasms/diagnosis
Chemical Substances	Prostate-Specific Antigen (EC 3.4.21.77) ; Protein Precursors ; Biomarkers, Tumor ; Protein Isoforms
Language	French
Publishing date	2023-02-09
Publishing country	France
Document type	Journal Article ; Review
ZDB-ID	418098-7
ISSN	1950-6112 ; 0003-3898
ISSN (online)	1950-6112
ISSN	0003-3898
DOI	10.1684/abc.2023.1782
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.203: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The extracellular domain of Her2 in serum as a biomarker of breast cancer.

Perrier, Alexandre / Gligorov, Joseph / Lefèvre, Guillaume / Boissan, Mathieu

Laboratory investigation; a journal of technical methods and pathology

2018 Volume 98, Issue 6, Page(s) 696–707

Abstract: Breast cancer is a major health problem worldwide. In ~15% of breast cancers, the epidermal growth factor receptor HER2, a transmembrane protein, is overexpressed. This HER2 overexpression is associated with an aggressive form of the disease and a poor ... ...

Abstract	Breast cancer is a major health problem worldwide. In ~15% of breast cancers, the epidermal growth factor receptor HER2, a transmembrane protein, is overexpressed. This HER2 overexpression is associated with an aggressive form of the disease and a poor clinical prognosis. The extracellular domain (ECD) of HER2 is released into the blood by a proteolytic mechanism known as "ECD shedding". This proteolytic shedding leaves a constitutively active truncated receptor in the membrane that is 10-100-fold more oncogenic than the full-length receptor and promotes the growth and survival of cancer cells. Shedding of the HER2 ECD is increased during metastasis: whereas 15% of primary breast cancer patients have elevated levels of serum HER2 ECD (sHER2 ECD), the levels reach 45% in patients with metastatic disease. Thus, sHER2 ECD has been proposed as a promising biomarker for cancer recurrence and for monitoring the disease status of patients overexpressing HER2. Nevertheless, in 2016, the American Society of Clinical Oncology advises clinicians not to use soluble HER2 levels to guide their choice of adjuvant therapy for patients with HER2-positive breast cancer, because the evidence was considered not strong enough. Currently, biomarkers such as carcinoembryonic antigen and cancer antigen 15-3 are widely used to monitor metastatic breast cancer disease even if the level of evidence of clinical impact of this monitoring is poor. In this article, we review the evidence that sHER2 ECD might be used in some situations as a biomarker for breast cancer. Although this serum biomarker will not replace the direct measurement of tumor HER2 status for diagnosis of early-stage tumors; it might be especially useful in metastatic disease for prognosis, as an indicator of cancer progression and of therapy response, particularly to anti-HER2 therapies. Owing to these data, sHER2 ECD should be considered as a promising biomarker to detect cancer recurrence and metastasis.
MeSH term(s)	Biomarkers, Tumor/blood ; Breast Neoplasms/blood ; Breast Neoplasms/diagnosis ; Breast Neoplasms/pathology ; Drug Resistance, Neoplasm ; Female ; Humans ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Prognosis ; Protein Domains ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/blood ; Receptor, ErbB-2/chemistry
Chemical Substances	Biomarkers, Tumor ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
Language	English
Publishing date	2018-02-28
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	80178-1
ISSN	1530-0307 ; 0023-6837
ISSN (online)	1530-0307
ISSN	0023-6837
DOI	10.1038/s41374-018-0033-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.164: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The NDPK/NME superfamily: state of the art.

Boissan, Mathieu / Schlattner, Uwe / Lacombe, Marie-Lise

Laboratory investigation; a journal of technical methods and pathology

2018 Volume 98, Issue 2, Page(s) 164–174

Abstract: Nucleoside diphosphate kinases (NDPK) are nucleotide metabolism enzymes encoded by NME genes (also called NM23). Given the fact that not all NME-encoded proteins are catalytically active NDPKs and that NM23 generally refers to clinical studies on ... ...

Abstract	Nucleoside diphosphate kinases (NDPK) are nucleotide metabolism enzymes encoded by NME genes (also called NM23). Given the fact that not all NME-encoded proteins are catalytically active NDPKs and that NM23 generally refers to clinical studies on metastasis, we use here NME/NDPK to denote the proteins. Since their discovery in the 1950's, NMEs/NDPKs have been shown to be involved in multiple physiological and pathological cellular processes, but the molecular mechanisms have not been fully determined. Recent progress in elucidating these underlying mechanisms has been presented by experts in the field at the 10th International Congress on the NDPK/NME/AWD protein family in October 2016 in Dubrovnik, Croatia, and is summarized in review articles or original research in this and an upcoming issue of Laboratory Investigation. Within this editorial, we discuss three major cellular processes that involve members of the multi-functional NME/NDPK family: (i) cancer and metastasis dissemination, (ii) membrane remodeling and nucleotide channeling, and iii) protein histidine phosphorylation.
MeSH term(s)	Animals ; Humans ; Isoenzymes/genetics ; Isoenzymes/metabolism ; Multigene Family ; Neoplasm Metastasis/genetics ; Neoplasms/enzymology ; Neoplasms/genetics ; Neoplasms/pathology ; Nucleoside-Diphosphate Kinase/genetics ; Nucleoside-Diphosphate Kinase/metabolism ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism
Chemical Substances	Isoenzymes ; Tumor Suppressor Proteins ; Nucleoside-Diphosphate Kinase (EC 2.7.4.6)
Language	English
Publishing date	2018-02-15
Publishing country	United States
Document type	Editorial ; Introductory Journal Article
ZDB-ID	80178-1
ISSN	1530-0307 ; 0023-6837
ISSN (online)	1530-0307
ISSN	0023-6837
DOI	10.1038/labinvest.2017.137
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.164: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Case report: Changes in the levels of stress hormones during Takotsubo syndrome.

Ruiz, Pablo / Gabarre, Paul / Chenevier-Gobeaux, Camille / François, Hélène / Kerneis, Mathieu / Cidlowski, John A / Oakley, Robert H / Lefèvre, Guillaume / Boissan, Mathieu

Frontiers in cardiovascular medicine

2022 Volume 9, Page(s) 931054

Abstract: Background: Takotsubo syndrome is an acute cardiac condition usually involving abnormal regional left ventricular wall motion and impaired left ventricular contractility. It is due mainly to hyper-stimulation of the sympathetic nerve system, inducing an ...

Abstract	Background: Takotsubo syndrome is an acute cardiac condition usually involving abnormal regional left ventricular wall motion and impaired left ventricular contractility. It is due mainly to hyper-stimulation of the sympathetic nerve system, inducing an excess of catecholamines, usually triggered by intense psychological or physiological stress. The relationship between Takotsubo syndrome and the circulating stress hormones cortisol and copeptin (a surrogate marker of arginine vasopressin) has not been well documented. Case summary: Here, we describe the dynamic changes in circulating cortisol and copeptin during an entire episode of Takotsubo syndrome in a post-partum woman after spontaneous vaginal delivery. The patient was diagnosed with inverted Takotsubo syndrome accompanied by HELLP syndrome. We found qualitative and quantitative changes in cortisol: a loss of circadian rhythm and a three-fold elevation in the plasma concentration of the hormone with a peak appearing several hours before circulating cardiac biomarkers began to rise. By contrast, levels of copeptin remained normal during the entire episode. Discussion: Our findings indicate that the levels of cortisol change during Takotsubo syndrome whereas those of copeptin do not. This association between elevated cortisol and Takotsubo syndrome suggests that aberrant levels of this stress hormone may contribute to the observed cardiac pathology. We conclude that biochemical assays of circulating cortisol and cardiac biomarkers may be a useful complement to the diagnosis of Takotsubo syndrome by non-invasive cardiac imaging.
Language	English
Publishing date	2022-07-22
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2022.931054
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques.

Perrier, Alexandre / Hainaut, Pierre / Lamy, Pierre-Jean / Guenoun, Alexandre / Nguyen, Dinh-Phong / Guerber, Fabrice / Troalen, Frédéric / Denis, Jérôme Alexandre / Boissan, Mathieu

Bulletin du cancer

2022 Volume 109, Issue 2, Page(s) 151–169

Abstract: In oncology, the identification of targets that correlate with a type of cancer has led to a profound change in the notion of "tumor markers". Technological advances, in particular the development of high-throughput sequencing, have led to the emergence ... ...

Title translation	Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores.
Abstract	In oncology, the identification of targets that correlate with a type of cancer has led to a profound change in the notion of "tumor markers". Technological advances, in particular the development of high-throughput sequencing, have led to the emergence of a new generation of molecular biomarkers for tumors. Despite their limited utility for screening and diagnosis, conventional tumor markers remain interesting for evaluation of prognoses, the choice and optimization of treatments, as well as for monitoring the effectiveness of those treatments. In this article, we revisit the conventional serum markers that are enjoying a 'come back' thanks to the development of high-performance scores based on biological, cytological, clinical, or radiological criteria.
MeSH term(s)	Biomarkers, Tumor/blood ; France ; High-Throughput Nucleotide Sequencing ; Humans ; Medical Oncology/methods ; Neoplasm Proteins/blood ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasms/blood ; Neoplasms/diagnosis ; Neoplasms/immunology ; Neoplasms/therapy ; Organ Specificity ; Precision Medicine/methods ; Predictive Value of Tests ; Prognosis ; Reproducibility of Results ; Treatment Outcome
Chemical Substances	Biomarkers, Tumor ; Neoplasm Proteins
Language	French
Publishing date	2022-01-07
Publishing country	France
Document type	Journal Article ; Review
ZDB-ID	213270-9
ISSN	1769-6917 ; 0007-4551
ISSN (online)	1769-6917
ISSN	0007-4551
DOI	10.1016/j.bulcan.2021.11.010
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.15: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: En marche vers une oncologie personnalisée : l’apport des techniques génomiques et de l’intelligence artificielle dans l’usage des biomarqueurs tumoraux circulants.

Perrier, Alexandre / Hainaut, Pierre / Guenoun, Alexandre / Nguyen, Dinh-Phong / Lamy, Pierre-Jean / Guerber, Fabrice / Troalen, Frédéric / Denis, Jérôme Alexandre / Boissan, Mathieu

Bulletin du cancer

2022 Volume 109, Issue 2, Page(s) 170–184

Abstract: Technological advances, in particular the development of high-throughput sequencing, have led to the emergence of a new generation of molecular biomarkers for tumors. These new tools have profoundly changed therapeutic management in oncology, with ... ...

Title translation	Moving towards a personalized oncology: The contribution of genomic techniques and artificial intelligence in the use of circulating tumor biomarkers.
Abstract	Technological advances, in particular the development of high-throughput sequencing, have led to the emergence of a new generation of molecular biomarkers for tumors. These new tools have profoundly changed therapeutic management in oncology, with increasingly precise molecular characterization of tumors leading to increasingly personalized therapeutic targeting. Detection of circulating tumor cells and/or circulating tumor DNA in blood samples -so-called 'liquid biopsies'- can now provide a genetic snapshot of the patient's tumor through an alternative and less invasive procedure than biopsy of the tumor tissue itself. This procedure for characterizing and monitoring the disease in real time facilitates the search for possible relapses, the emergence of resistance, or emergence of a new therapeutic target. In the long term, it might also provide a means of early detection of cancer. These new approaches require the treatment of ever-increasing amounts of clinical data, notably, with the goal of calculating composite clinical-biological predictive scores. The use of artificial intelligence will be unavoidable in this domain, but it raises ethical questions and implications for the health-care system that will have to be addressed.
MeSH term(s)	Artificial Intelligence/ethics ; Artificial Intelligence/trends ; Biomarkers, Tumor/blood ; Circulating Tumor DNA/blood ; Data Management ; Early Detection of Cancer/methods ; High-Throughput Nucleotide Sequencing/trends ; Humans ; Immunotherapy ; Liquid Biopsy/methods ; Medical Oncology/methods ; Medical Oncology/trends ; MicroRNAs/blood ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasms/blood ; Neoplasms/genetics ; Neoplasms/therapy ; Neoplastic Cells, Circulating ; Precision Medicine/trends
Chemical Substances	Biomarkers, Tumor ; Circulating Tumor DNA ; MicroRNAs
Language	French
Publishing date	2022-01-13
Publishing country	France
Document type	Journal Article ; Review
ZDB-ID	213270-9
ISSN	1769-6917 ; 0007-4551
ISSN (online)	1769-6917
ISSN	0007-4551
DOI	10.1016/j.bulcan.2021.12.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.15: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: RSK3 switches cell fate: from stress-induced senescence to malignant progression.

Huna, Anda / Flaman, Jean-Michel / Lodillinsky, Catalina / Zhu, Kexin / Makulyte, Gabriela / Pakulska, Victoria / Coute, Yohann / Ruisseaux, Clémence / Saintigny, Pierre / Hernandez-Vargas, Hector / Defossez, Pierre-Antoine / Boissan, Mathieu / Martin, Nadine / Bernard, David

Journal of experimental & clinical cancer research : CR

2023 Volume 42, Issue 1, Page(s) 318

Abstract: Background: TGFβ induces several cell phenotypes including senescence, a stable cell cycle arrest accompanied by a secretory program, and epithelial-mesenchymal transition (EMT) in normal epithelial cells. During carcinogenesis cells lose the ability to ...

Abstract	Background: TGFβ induces several cell phenotypes including senescence, a stable cell cycle arrest accompanied by a secretory program, and epithelial-mesenchymal transition (EMT) in normal epithelial cells. During carcinogenesis cells lose the ability to undergo senescence in response to TGFβ but they maintain an EMT, which can contribute to tumor progression. Our aim was to identify mechanisms promoting TGFβ-induced senescence escape. Methods: In vitro experiments were performed with primary human mammary epithelial cells (HMEC) immortalized by hTert. For kinase library screen and modulation of gene expression retroviral transduction was used. To characterize gene expression, RNA microarray with GSEA analysis and RT-qPCR were used. For protein level and localization, Western blot and immunofluorescence were performed. For senescence characterization crystal violet assay, Senescence Associated-β-Galactosidase activity, EdU staining were conducted. To determine RSK3 partners FLAG-baited immunoprecipitation and mass spectrometry-based proteomic analyses were performed. Proteosome activity and proteasome enrichment assays were performed. To validate the role of RSK3 in human breast cancer, analysis of METABRIC database was performed. Murine intraductal xenografts using MCF10DCIS.com cells were carried out, with histological and immunofluorescence analysis of mouse tissue sections. Results: A screen with active kinases in HMECs upon TGFβ treatment identified that the serine threonine kinase RSK3, or RPS6KA2, a kinase mainly known to regulate cancer cell death including in breast cancer, reverted TGFβ-induced senescence. Interestingly, RSK3 expression decreased in response to TGFβ in a SMAD3-dependent manner, and its constitutive expression rescued SMAD3-induced senescence, indicating that a decrease in RSK3 itself contributes to TGFβ-induced senescence. Using transcriptomic analyses and affinity purification coupled to mass spectrometry-based proteomics, we unveiled that RSK3 regulates senescence by inhibiting the NF-κΒ pathway through the decrease in proteasome-mediated IκBα degradation. Strikingly, senescent TGFβ-treated HMECs display features of epithelial to mesenchymal transition (EMT) and during RSK3-induced senescence escaped HMECs conserve EMT features. Importantly, RSK3 expression is correlated with EMT and invasion, and inversely correlated with senescence and NF-κΒ in human claudin-low breast tumors and its expression enhances the formation of breast invasive tumors in the mouse mammary gland. Conclusions: We conclude that RSK3 switches cell fate from senescence to malignancy in response to TGFβ signaling.
MeSH term(s)	Animals ; Female ; Humans ; Mice ; Breast Neoplasms/pathology ; Epithelial-Mesenchymal Transition/genetics ; Mammary Neoplasms, Animal ; Proteasome Endopeptidase Complex/metabolism ; Proteomics ; Signal Transduction ; Transforming Growth Factor beta/metabolism
Chemical Substances	Proteasome Endopeptidase Complex (EC 3.4.25.1) ; Transforming Growth Factor beta ; ribosomal protein S6 kinase, 90kDa, polypeptide 3 (EC 2.7.11.1)
Language	English
Publishing date	2023-11-27
Publishing country	England
Document type	Journal Article
ZDB-ID	803138-1
ISSN	1756-9966 ; 0392-9078
ISSN (online)	1756-9966
ISSN	0392-9078
DOI	10.1186/s13046-023-02909-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2065: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The mitochondrial nucleoside diphosphate kinase (NDPK-D/NME4), a moonlighting protein for cell homeostasis.

Lacombe, Marie-Lise / Tokarska-Schlattner, Malgorzata / Boissan, Mathieu / Schlattner, Uwe

Laboratory investigation; a journal of technical methods and pathology

2018 Volume 98, Issue 5, Page(s) 582–588

Abstract: Mitochondrial nucleoside diphosphate kinase (NDPK-D; synonyms: NME4, NM23-H4) represents the major mitochondrial NDP kinase. The homohexameric complex emerged as a protein with multiple functions in bioenergetics and phospholipid signaling. It occurs at ... ...

Abstract	Mitochondrial nucleoside diphosphate kinase (NDPK-D; synonyms: NME4, NM23-H4) represents the major mitochondrial NDP kinase. The homohexameric complex emerged as a protein with multiple functions in bioenergetics and phospholipid signaling. It occurs at different but precise mitochondrial locations and can affect among other mitochondrial shapes and dynamics, as well as the specific elimination of defective mitochondria or cells via mitophagy or apoptosis. With these various functions in cell homeostasis, NDPK-D/NME4 adds to the group of so-called moonlighting (or gene sharing) proteins.
MeSH term(s)	Animals ; Apoptosis ; Homeostasis ; Humans ; Mitophagy ; Neoplasms/pathology ; Nucleoside Diphosphate Kinase D/analysis ; Nucleoside Diphosphate Kinase D/chemistry ; Nucleoside Diphosphate Kinase D/genetics ; Nucleoside Diphosphate Kinase D/physiology ; Phospholipids/chemistry
Chemical Substances	Phospholipids ; NME4 protein, human (EC 2.7.4.6) ; Nucleoside Diphosphate Kinase D (EC 2.7.4.6)
Language	English
Publishing date	2018-02-28
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	80178-1
ISSN	1530-0307 ; 0023-6837
ISSN (online)	1530-0307
ISSN	0023-6837
DOI	10.1038/s41374-017-0004-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.164: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito